Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
45 Leser
Artikel bewerten:
(0)

Rani Therapeutics' Secures Series C Funding

-- Investment to Accelerate Development of Breakthrough Oral Biotherapeutics Platform

SAN JOSE, California, May 26, 2015 /PRNewswire/ --Rani Therapeutics today announced it has closed its Series C round of funding. Participants included Novartis, Google Ventures, InCube Ventures, a life sciences venture fund, and VentureHealth, an online venture fund, as well as a number of additional investors.

"We are entering into an exciting new stage of growth for Rani, and this funding will help us continue to de-risk our platform and create the manufacturing infrastructure we need for clinical trials and beyond," said Mir Imran, Chairman & CEO, Rani Therapeutics. "We are committed to delivering on our promise to radically transform how biologic drugs are delivered to millions of patients, and this financing is an important step forward."

The company also recently announced a collaboration partnership with Novartis, including feasibility studies to evaluate how selected Novartis proprietary biologics can be delivered into the bloodstream using Rani's unique route of administration.

"Today we are in an age where advances in life sciences are increasing at an unprecedented rate," said Blake Byers, General Partner at Google Ventures. "We are excited by the team's strong track record in pre-clinical studies and look forward to the day Rani will improve the lives of patients."

Other investors in this financing include The Stevanato Group, Crystal Horizon Investments, Pinemount Investments, and Pacific Venture Opportunity Fund, as well as Buttonwood Funds, which joined as a follow-on investor.

About Rani Therapeutics

Rani Therapeutics has developed a novel approach for the oral delivery of peptides, proteins and therapeutic antibodies, which to date can only be delivered through injections. The approach and technology for Rani Therapeutics was created atInCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur and investor.For more information, please go to www.ranitherapeutics.com.

Contact: Stephanie McGrory, +1.408.457.3730, stephanie@incubelabs.com

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.